- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06260709
En forskningsstudie för att titta på långtidsbehandling med ett läkemedel som heter NNC6019-0001 för personer som har hjärtsvikt på grund av transtyretin amyloidos
Open-label förlängningsstudie av långsiktig säkerhet och effekt av NNC6019-0001 hos deltagare med transtyretin amyloid kardiomyopati (ATTR CM)
This study will test a medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis. It will look at how safe this medicine is in the long term and if it can reduce symptoms of a heart disease due to TTR amyloidosis, such as heart failure. It is an extension to a study called "A research study to look at how a new medicine called NNC6019-0001 works and how safe it is for people who have a heart disease due to TTR amyloidosis". Only participants who have completed that study will be invited for this new study. Participants will get NNC6019-0001, regardless of whether they got placebo or NNC6019-0001 in the first study. The study will last for approximately 6 years or until NNC6019-0001 is commercially or otherwise available to the participant, whichever comes first.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Créteil, Frankrike, 94000
- Ap-Hp-Hopital Henri Mondor
-
Toulouse, Frankrike, 31059
- Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil
-
Toulouse, Frankrike, 31059
- Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil-1
-
-
-
-
Arizona
-
Phoenix, Arizona, Förenta staterna, 85054
- Mayo Clinic Arizona
-
-
California
-
Los Angeles, California, Förenta staterna, 90048
- Cedars-Sinai Medical Center_Los Angeles
-
Stanford, California, Förenta staterna, 94305
- Stanford Hlth Cre-Boswell Clin
-
-
Florida
-
Jacksonville, Florida, Förenta staterna, 32224
- Mayo Clinic Jacksonville
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60611
- NW Univ-Bluhm Cardiovasc Inst
-
Evanston, Illinois, Förenta staterna, 60208
- NW Univ-Bluhm Cardiovasc Inst
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21201
- Univ of MD Schl of Med
-
-
Minnesota
-
Rochester, Minnesota, Förenta staterna, 55905
- Mayo Clinic Rochester
-
-
-
-
PV
-
Pavia, PV, Italien, 27100
- Centro per lo Studio e la Cura delle Amiloidosi Sistemiche Fondazione IRCCS Policlinico San Matteo
-
-
Pi
-
Pisa, Pi, Italien, 56124
- Fondazione CNR-Regione Toscana Gabriele Monasterio
-
Pisa, Pi, Italien, 56124
- Fondazione Toscana Gabriele Monasterio - Dipartimento Cardiotoracico - UOC Cardiologia e Medicina Cardiovascolare
-
-
-
-
-
Fukuoka, Japan, 807-8556
- Hospital of the University of Occupational and Environmental Health, Cardiology, Nephrology
-
Hiroshima, Japan, 734-8551
- Hiroshima University hospital, Cardiovascular Medicine
-
Hiroshima, Japan, 734-8551
- Hiroshima University hospital_Cardiovascular Medicine
-
Kumamoto-shi, Kumamoto, Japan, 860-8556
- Kumamoto University Hospital, Cardiovascular Medicine
-
Nagano, Japan, 390-8621
- Shinshu University Hospital, Department of Neurology
-
Nagasaki, Japan, 852-8501
- Nagasaki University Hospital, Cardiovascular Medicine
-
Okayama, Japan, 700-8558
- Okayama University Hospital_Cardiovascular Medicine
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N 4Z6
- University of Calgary_Cardiology
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V5Z 1M9
- Ctr for Cardiovascular Innovation
-
-
-
-
-
Groningen, Nederländerna, 9713 GZ
- UMC Groningen
-
Utrecht, Nederländerna, 3584 CX
- UMC Utrecht
-
Utrecht, Nederländerna, 3584 CX
- Universitair Medisch Centrum Utrecht
-
-
-
-
-
Guimarães, Portugal, 4835-044
- Hospital da Senhora da Oliveira - Guimarães
-
Guimarães, Portugal, 4835-044
- ULS Do Alto Ave, E.P.E. - Hospital Senhora da Oliveira - Guimarães
-
Vila Real, Portugal, 5000-508
- ULS De Tras-Os-Montes E Alto Douro E.P.E. - Unidade Hospitalar de Vila Real
-
-
-
-
Madrid
-
Majadahonda, Madrid, Spanien, 28222
- Hospital Universitario Puerta de Hierro Majadahonda
-
-
-
-
-
Prague, Tjeckien, 12808
- II. interni klinika VFN - Kardiologie a angiologie
-
-
-
-
-
Heidelberg, Tyskland, 69120
- Universitätsklinik Heidelberg Innere Medizin III Kardiologie, Angiologie, Pneumologie
-
Heidelberg, Tyskland, 69120
- UniklinikHeidelberg - Innere Med. III - Kardiologie, Angiologie, Pneumologie
-
München, Tyskland, 81377
- LMU Klinikum München Klinik und Poliklinik 1
-
Münster, Tyskland, 48149
- Uniklinik Münster, Klinik für Kardiologie I
-
Münster, Tyskland, 48149
- Universitätsklinikum Münster - Klinik für Kardiologie I
-
Würzburg, Tyskland, 97078
- Universitatsklinikum Würzburg - Zentrum für Herzinsuffizienz
-
Würzburg, Tyskland, 97078
- Universitatsklinikum Wurzburg AöR
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Completed study intervention in NN6019-4940 and attended the last study visit (week 64; visit 16), and no later than 12 weeks after visit 16.
- Expected to be on stable doses of cardiovascular medical therapy 6 weeks prior to the enrolment visit.
Exclusion Criteria:
- A prior solid organ transplant.
- Presence or history of malignant neoplasm (other than basal or squamous cell skin cancer, in-situ carcinomas of the cervix, or in-situ/high grade prostatic intraepithelial neoplasia (PIN) or low-grade prostate cancer) within 5 years before screening.
- Current treatment with calcium channel blockers with conduction system effects (e.g., verapamil, diltiazem). The use of dihydropyridine calcium channel blockers is allowed. The use of digoxin will only be allowed if required for management of atrial fibrillation with rapid ventricular response.
- Body weight greater than (>) 120 kilograms (kg) (264.6 pounds [lb]) at screening.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: NNC6019-0001
Participants will receive NNC6019-0001 intravenously every 4 weeks added to the standard of care up to 300 weeks. |
Intravenous NNC6019-0001 every 4 weeks added to the standard of care up to 300 weeks. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of Treatment Emergent Adverse Events (TEAEs)
Tidsram: From baseline (week 0) to up to 6 years
|
Measured as events. |
From baseline (week 0) to up to 6 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in 6-Minute Walk Test (6MWT)
Tidsram: From baseline (week 0) to visit 28 (week 104)
|
Measured in meters. |
From baseline (week 0) to visit 28 (week 104)
|
|
Change in N-terminal-pro brain natriuretic peptide (NT-proBNP)
Tidsram: From baseline (week 0) to visit 28 (week 104)
|
Measured in percentage. |
From baseline (week 0) to visit 28 (week 104)
|
|
Change in Myocardial Extracellular Volume (ECV)
Tidsram: From baseline (week 0) to visit 28 (week 104)
|
Measured in percentage-points. |
From baseline (week 0) to visit 28 (week 104)
|
|
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS)
Tidsram: From baseline (week 0) to visit 28 (week 104)
|
The KCCQ is a disease-specific health status instrument composed of 23 items that quantify the domains of physical limitation, symptoms, self-efficacy, social limitation, and health-related quality of life limitation from heart failure. The overall summary score and all domains have been independently demonstrated to be valid, reliable, and responsive to clinical change. CSS scores range from 0 to 100 and lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life. Measured in score on a scale. |
From baseline (week 0) to visit 28 (week 104)
|
|
Change in Troponin I
Tidsram: From baseline (week 0) to visit 28 (week 104)
|
Measured in nanogram per milliliter (ng/mL). |
From baseline (week 0) to visit 28 (week 104)
|
|
Change in Global Longitudinal Strain (GLS) on Echocardiography
Tidsram: From baseline (week 0) to visit 28 (week 104)
|
Measured in percentage-points. |
From baseline (week 0) to visit 28 (week 104)
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- NN6019-7565
- 2022-502605-15-00 (Annan identifierare: European Medical Agency (EMA))
- U1111-1284-5820 (Annan identifierare: World Health Organization (WHO))
- jRCT2071240078 (Registeridentifierare: JRCT)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .